First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: OrthoPediatrics: the story is balanced — Quarterly revenue growth rates and guidance - market expects sustained 20-30%+ growth to justify valuation; any…
★ Analysts see FY2026 revenue reaching $265M — +12.2% growth in a single year.
What Moves the Stock
1Quarterly revenue growth rates and guidance - market expects sustained 20-30%+ growth to justify valuation; any deceleration triggers selloffs
2New product launches and FDA clearances - particularly in higher-margin spine segment or international expansion products
3Acquisition announcements - KIDS has been serial acquirer of pediatric portfolios (Orthex, Vilex, Telos); integration success and revenue synergies drive sentiment
4Surgeon adoption metrics and sales force productivity - new surgeon adds and revenue per rep indicate market penetration progress
5Path to profitability updates - with negative FCF of -9.6%, investors focus on timeline to positive operating cash flow and EBITDA breakeven
6Trauma and deformity products (estimated 50-55% of revenue): plates, screws, external fixation systems for fractures and limb deformities
7Scoliosis and spine products (estimated 40-45% of revenue): spinal implants, growing rod systems, fusion devices for pediatric spinal conditions
8Sports medicine and other products (estimated 5-10% of revenue): ACL reconstruction, soft tissue repair for adolescent athletes
growth - Investors are paying 1.9x price/sales for a company with 37.6% revenue growth but negative profitability…
Rising rates create moderate headwinds through two channels: (1) Higher cost of capital pressures valuation multiples for unprofitable…
Watch on earnings: Quarterly revenue growth rate (organic vs acquisition-driven) - sustained 25%+ growth needed to support current valuation, Gross margin percentage - watch for compression below 70% signaling pricing pressure or unfavorable product mix shifts, Operating cash flow trajectory - path from current negative to breakeven indicates business model sustainability without capital raises.
One Sentence Summary:
OrthoPediatrics: the story is balanced — quarterly revenue growth rates and guidance - market expects sustained 20-30%+ growth to justify valuation; any deceleration triggers.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.